NCT00664573View on ClinicalTrials.gov

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

PHASE2TerminatedINTERVENTIONAL
Enrollment

339

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Baminercept alfa (BG9924)

dosage administered as per Biogen-Idec protocol

Trial Locations (8)

62270

Coordinating Research Site, Cuernavaca

127644

Coordinating Research Site, Moscow

810112

Coordinating Research Site, Brăila

T4000AXL

Coordinating Research Site, San Miguel de Tucumán

Unknown

Coordinating Research Site, São Paulo

H-1036

Coordinating Research Site, Budapest

87-100

Coordinating Research Site, Torun

LS74SA

Coordinating Research Site, Leeds

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY